{
  "meta": {
    "data_length": 1,
    "message": "Statement id stmt:hse:00840:b:0 retrieved successfully",
    "request_url": "https://api.moalmanac.org/statements?statement_id=stmt%3Ahse%3A00840%3Ab%3A0",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.002149,
    "timestamp_received": "2026-10-17T00:04:35.940656+00:00Z",
    "timestamp_returned": "2026-10-17T00:04:35.942805+00:00Z",
    "trace_id": "b88c6b4d-74cf-4d40-ba84-703af3a6e700"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://moalmanac.org",
    "last_updated": "2026-08-02"
  },
  "data": [
    {
      "id": "stmt:hse:00840:b:0",
      "type": "Statement",
      "description": "The Republic of Ireland's Health Service Executive (HSE) has approved acalabrutinib (tablets) for reimbursement as a monotherapy treatment option for the treatment of previously untreated adult patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or TP53 mutation who are unsuitable for chemoimmunotherapy.",
      "contributions": [
        {
          "id": "ctrb:vanallenlab:2024-01-16:0",
          "type": "Contribution",
          "description": "Adding HSE approvals for reimbursement to database",
          "date": "2024-01-16",
          "contributor": {
            "id": "agent:user:vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute"
          }
        },
        {
          "id": "ctrb:hse:2023-07-01:0",
          "type": "Contribution",
          "description": "Indication approved for reimbursement.",
          "date": "2023-07-01",
          "contributor": {
            "id": "agent:org:hse",
            "type": "Agent",
            "agentType": "organization",
            "name": "Health Service Executive",
            "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland."
          }
        }
      ],
      "reportedIn": [
        {
          "id": "doc:hse:00840",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Acalabrutinib (Tablets) Monotherapy. NCCP National SACT Regimen. HSE.",
          "title": null,
          "aliases": [],
          "description": "Acalabrutinib (Tablets) Monotherapy, 2024, version number 2, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/7006/840_v2_Acalabrutinib_tablets.pdf",
          "urls": [
            "https://healthservice.hse.ie/documents/7006/840_v2_Acalabrutinib_tablets.pdf"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "agent:org:hse",
                "type": "Agent",
                "agentType": "organization",
                "name": "Health Service Executive",
                "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland."
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": null,
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": null,
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": null,
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": null,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2023-12-13",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      ],
      "direction": "supports",
      "proposition": {
        "id": "prop:vtxr:744",
        "type": "VariantTherapeuticResponseProposition",
        "predicate": "predictsSensitivityTo",
        "subjectVariant": {
          "type": "CategoricalVariant",
          "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition."
        },
        "conditionQualifier": {
          "id": "dis:ncit:C3163",
          "conceptType": "Disease",
          "name": "Chronic Lymphocytic Leukemia",
          "mappings": [
            {
              "relation": "closeMatch",
              "coding": {
                "id": "coding:ncit:C7540",
                "code": "C7540",
                "name": "Small Lymphocytic Lymphoma",
                "system": "https://evsexplore.semantics.cancer.gov",
                "systemVersion": "26.08e",
                "iris": [
                  "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C7540"
                ]
              }
            },
            {
              "relation": "broadMatch",
              "coding": {
                "id": "coding:oncotree:CLLSLL",
                "code": "CLLSLL",
                "name": "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
                "system": "https://oncotree.mskcc.org",
                "systemVersion": "oncotree_2025_10_03",
                "iris": [
                  "https://oncotree.mskcc.org/?version=oncotree_2025_10_03&field=NAME&search=Chronic+Lymphocytic+Leukemia%2FSmall+Lymphocytic+Lymphoma+%28CLLSLL%29"
                ]
              }
            }
          ],
          "extensions": [
            {
              "name": "solid_tumor",
              "value": false,
              "description": "Boolean value for if this tumor type is categorized as a solid tumor."
            }
          ],
          "primaryCoding": {
            "id": "coding:ncit:C3163",
            "code": "C3163",
            "name": "Chronic Lymphocytic Leukemia",
            "system": "https://evsexplore.semantics.cancer.gov",
            "systemVersion": "26.08e",
            "iris": [
              "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C3163"
            ]
          }
        },
        "objectTherapeutic": {
          "id": "tx:ncit:C113442",
          "conceptType": "Therapy",
          "name": "Acalabrutinib",
          "mappings": [
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "coding:rxcui:1986808",
                "code": "1986808",
                "name": "acalabrutinib",
                "system": "RxNorm",
                "systemVersion": "02-Mar-2026",
                "iris": [
                  "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1986808"
                ]
              }
            },
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "coding:omop:792764",
                "code": "792764",
                "name": "acalabrutinib",
                "system": "OMOP",
                "systemVersion": "v20260227",
                "iris": [
                  "https://athena.ohdsi.org/search-terms/terms/792764"
                ]
              }
            }
          ],
          "extensions": [
            {
              "name": "therapy_strategy",
              "value": [
                "BTK inhibition"
              ],
              "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
              "name": "therapy_type",
              "value": "Targeted therapy",
              "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
          ],
          "primaryCoding": {
            "id": "coding:ncit:C113442",
            "code": "C113442",
            "name": "Acalabrutinib",
            "system": "https://evsexplore.semantics.cancer.gov",
            "systemVersion": "26.08e",
            "iris": [
              "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C113442"
            ]
          }
        },
        "extensions": [
          {
            "name": "biomarkers",
            "value": [
              {
                "id": "bmkr.criterion:80",
                "present": true,
                "subject": {
                  "id": "bmkr:80",
                  "type": "CategoricalVariant",
                  "name": "TP53 Somatic variants",
                  "constraints": [
                    {
                      "type": "DefiningLocationConstraint",
                      "location": {
                        "id": "ga4gh:SL.-oJnRI__rvXIYjpwdDBxIjQ0O8Qm-Imi",
                        "type": "SequenceLocation",
                        "name": null,
                        "aliases": [],
                        "description": "Sequence spanning the length of refseq:NP_000537.3, the protein product of the MANE Select coding transcript for TP53 (refseq:NM_000546.6).",
                        "digest": "-oJnRI__rvXIYjpwdDBxIjQ0O8Qm-Imi",
                        "sequenceReference": {
                          "id": "ga4gh:SQ.KAxM06sYzBF6zFftFaYq9E_18wsnn7al",
                          "type": "SequenceReference",
                          "name": "NP_000537.3",
                          "aliases": [
                            "ensembl:ENSP00000269305.4",
                            "ga4gh:SQ.KAxM06sYzBF6zFftFaYq9E_18wsnn7al",
                            "refseq:NP_000537.3"
                          ],
                          "description": "The protein product of the MANE Select coding transcript for TP53 (refseq:NM_000546.6), corresponding to the Refseq protein accession NP_000537.3.",
                          "moleculeType": "protein",
                          "refgetAccession": "SQ.KAxM06sYzBF6zFftFaYq9E_18wsnn7al",
                          "residueAlphabet": "aa"
                        },
                        "start": 0,
                        "end": 393,
                        "sequence": null
                      },
                      "relations": [],
                      "matchCharacteristic": {
                        "primaryCoding": {
                          "code": "is_within",
                          "system": "ga4gh-gks-term:location-match"
                        }
                      }
                    },
                    {
                      "type": "FeatureContextConstraint",
                      "featureContext": {
                        "id": "gene:hgnc:11998",
                        "conceptType": "Gene",
                        "name": "TP53",
                        "primaryCoding": {
                          "id": "coding:hgnc:11998",
                          "code": "HGNC:11998",
                          "system": "https://genenames.org",
                          "iris": [
                            "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11998"
                          ]
                        },
                        "mappings": [
                          {
                            "relation": "exactMatch",
                            "coding": {
                              "id": "coding:ensembl:ensg00000141510",
                              "code": "ENSG00000141510",
                              "system": "https://www.ensembl.org",
                              "iris": [
                                "https://www.ensembl.org/id/ENSG00000141510"
                              ]
                            }
                          },
                          {
                            "relation": "exactMatch",
                            "coding": {
                              "id": "coding:ncbi:7157",
                              "code": "7157",
                              "system": "https://www.ncbi.nlm.nih.gov/gene",
                              "iris": [
                                "https://www.ncbi.nlm.nih.gov/gene/7157"
                              ]
                            }
                          },
                          {
                            "relation": "relatedMatch",
                            "coding": {
                              "id": "coding:refseq:NM_000546.6",
                              "code": "NM_000546.6",
                              "system": "https://www.ncbi.nlm.nih.gov/nuccore",
                              "iris": [
                                "https://www.ncbi.nlm.nih.gov/nuccore/NM_000546.6"
                              ]
                            }
                          }
                        ]
                      }
                    }
                  ],
                  "extensions": [
                    {
                      "name": "biomarker_type",
                      "value": "Somatic variant"
                    },
                    {
                      "name": "chromosome",
                      "value": "17"
                    },
                    {
                      "name": "start_position",
                      "value": null
                    },
                    {
                      "name": "end_position",
                      "value": null
                    },
                    {
                      "name": "reference_allele",
                      "value": null
                    },
                    {
                      "name": "alternate_allele",
                      "value": null
                    },
                    {
                      "name": "cdna_change",
                      "value": null
                    },
                    {
                      "name": "protein_change",
                      "value": null
                    },
                    {
                      "name": "variant_annotation",
                      "value": null
                    },
                    {
                      "name": "exon",
                      "value": null
                    },
                    {
                      "name": "rsid",
                      "value": null
                    },
                    {
                      "name": "hgvsg",
                      "value": null
                    },
                    {
                      "name": "hgvsc",
                      "value": null
                    },
                    {
                      "name": "requires_oncogenic",
                      "value": false
                    }
                  ]
                }
              }
            ],
            "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic."
          }
        ]
      },
      "strength": {
        "id": "str:ncit:C25425",
        "conceptType": "Evidence",
        "name": "Approval",
        "mappings": [],
        "primaryCoding": {
          "id": "coding:ncit:C25425",
          "code": "C25425",
          "name": "Approval",
          "system": "https://evsexplore.semantics.cancer.gov",
          "systemVersion": "26.08e",
          "iris": [
            "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425"
          ]
        }
      },
      "extensions": [
        {
          "name": "status",
          "value": "Active",
          "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db."
        },
        {
          "name": "indication",
          "value": {
            "id": "ind:hse:00840:b",
            "type": "Indication",
            "description": "As monotherapy for the treatment of previously untreated CLL in the presence of 17p deletion or TP53 mutation in adult patients unsuitable for chemoimmunotherapy.",
            "contributions": [
              {
                "id": "ctrb:vanallenlab:2024-01-16:0",
                "type": "Contribution",
                "description": "Adding HSE approvals for reimbursement to database",
                "date": "2024-01-16",
                "contributor": {
                  "id": "agent:user:vanallenlab",
                  "type": "Agent",
                  "agentType": "contributor",
                  "name": "Van Allen lab",
                  "description": "Van Allen lab, Dana-Farber Cancer Institute"
                }
              },
              {
                "id": "ctrb:hse:2023-07-01:0",
                "type": "Contribution",
                "description": "Indication approved for reimbursement.",
                "date": "2023-07-01",
                "contributor": {
                  "id": "agent:org:hse",
                  "type": "Agent",
                  "agentType": "organization",
                  "name": "Health Service Executive",
                  "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland."
                }
              }
            ],
            "reportedIn": [
              {
                "id": "doc:hse:00840",
                "type": "Document",
                "documentType": "Regulatory approval",
                "name": "Acalabrutinib (Tablets) Monotherapy. NCCP National SACT Regimen. HSE.",
                "title": null,
                "aliases": [],
                "description": "Acalabrutinib (Tablets) Monotherapy, 2024, version number 2, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/7006/840_v2_Acalabrutinib_tablets.pdf",
                "urls": [
                  "https://healthservice.hse.ie/documents/7006/840_v2_Acalabrutinib_tablets.pdf"
                ],
                "doi": null,
                "pmid": null,
                "extensions": [
                  {
                    "name": "agent",
                    "value": {
                      "id": "agent:org:hse",
                      "type": "Agent",
                      "agentType": "organization",
                      "name": "Health Service Executive",
                      "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland."
                    },
                    "description": "The organization that published this document."
                  },
                  {
                    "name": "company",
                    "value": "",
                    "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
                  },
                  {
                    "name": "drug_name_brand",
                    "value": null,
                    "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
                  },
                  {
                    "name": "drug_name_generic",
                    "value": null,
                    "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
                  },
                  {
                    "name": "first_publication_date",
                    "value": null,
                    "description": "The publication date for the initial version of this document."
                  },
                  {
                    "name": "identification_number",
                    "value": null,
                    "description": "Identification number used by the publishing organization."
                  },
                  {
                    "name": "publication_date",
                    "value": "2023-12-13",
                    "description": "The publication date for the document."
                  },
                  {
                    "name": "status",
                    "value": "Active",
                    "description": "Whether this document is Active or Deprecated within moalmanac-db."
                  }
                ]
              }
            ],
            "extensions": [
              {
                "name": "status",
                "value": "Approved",
                "description": "Current approval status."
              },
              {
                "name": "reimbursement_scheme",
                "value": "CDS",
                "description": "Current scheme used to reimburse indication."
              },
              {
                "name": "reimbursement_comment",
                "value": null,
                "description": "More details about the current reimbursement scheme(s)."
              }
            ]
          },
          "description": "The underlying Indication supporting this Statement."
        }
      ]
    }
  ]
}